Decreased serum human leukocyte antigen-G

Decreased serum human leukocyte antigen-G ranges are related to gestational diabetes mellitus 

Goal: This examine was designed to decide serum human leukocyte antigen-G (HLA-G) ranges and set up whether or not serum HLA-G stage is said with gestational diabetes mellitus (GDM).

Strategies: Twenty-five GDM sufferers aged between 24 and 34 years and 24 wholesome pregnant ladies aged between 22 and 33 years had been included on this examine. Well being standing of topics was decided by medical historical past, bodily, and obstetric examinations. Absence of household historical past for Sort 2 diabetes mellitus, absence of prognosis or medical proof of any main illness, and absence of remedy use altering glucose metabolism constituted the inclusion standards. GDM instances who’re at their 24-28 weeks of being pregnant and who haven’t been utilizing any oral hypoglycemic brokers had been included in GDM group. Management group consisted of wholesome pregnant ladies at their 24-28 weeks of being pregnant.

Outcomes: Ladies with GDM had considerably decrease ranges of serum HLA-G than controls. HLA-G ranges had been negatively correlated with all parameters of glucose metabolism together with insulin (r = – 0.14; p = 0.338), fasting blood glucose (r = – 0.220; p = 0.129), 1-h oral glucose tolerance take a look at (OGTT) blood glucose (r = – 0.18; p = 0.271), 2-h OGTT blood glucose (r = – 0.314; p = 0.172), homeostasis mannequin evaluation (r = – 0.226; p = 0.119), HbA1C (r = -0.342; p = 0.108), and WBC (r = -0.149; p = 0.307). There was a detrimental correlation between HLA-G and BMI (r = -0.341; p = 0.016).

Conclusion: Decreased circulating HLA-G stage is discovered to be related to insulin resistance and GDM, on this examine.

jointsjournal
jointsjournal

Human Carcinoembryonic Antigen (CEA) ELISA Kit

RDR-CEA-Hu-96Tests 96 Tests
EUR 500

Mouse Carcinoembryonic Antigen (CEA) ELISA Kit

RDR-CEA-Mu-48Tests 48 Tests
EUR 419

Mouse Carcinoembryonic Antigen (CEA) ELISA Kit

RDR-CEA-Mu-96Tests 96 Tests
EUR 578

Human Carcinoembryonic Antigen (CEA) ELISA Kit

RD-CEA-Hu-48Tests 48 Tests
EUR 350

Human Carcinoembryonic Antigen (CEA) ELISA Kit

RD-CEA-Hu-96Tests 96 Tests
EUR 479

Mouse Carcinoembryonic Antigen (CEA) ELISA Kit

RD-CEA-Mu-48Tests 48 Tests
EUR 402

Mouse Carcinoembryonic Antigen (CEA) ELISA Kit

RD-CEA-Mu-96Tests 96 Tests
EUR 553

Carcinoembryonic Antigen (CEA)

HY-P0277 5mg
EUR 1399

Carcinoembryonic Antigen (CEA)

MO47049 0.5 ml
EUR 349

Carcinoembryonic Antigen (CEA) Antibody

abx022526-01ml 0.1 ml
EUR 1107
  • Shipped within 5-10 working days.

Carcinoembryonic Antigen (CEA) Antibody

abx020536-1mg 1 mg
EUR 787
  • Shipped within 5-10 working days.

Carcinoembryonic Antigen (CEA) Antibody

abx020540-1mg 1 mg
EUR 787
  • Shipped within 5-10 working days.

Carcinoembryonic Antigen (CEA) Antibody

abx020541-1mg 1 mg
EUR 759
  • Shipped within 5-10 working days.

Carcinoembryonic Antigen (CEA) Antibody

abx020542-1mg 1 mg
EUR 690
  • Shipped within 5-10 working days.

Carcinoembryonic Antigen (CEA) Antibody

abx020543-1mg 1 mg
EUR 739
  • Shipped within 5-10 working days.

Carcinoembryonic Antigen (CEA) Antibody

abx020544-1mg 1 mg
EUR 690
  • Shipped within 5-10 working days.

Carcinoembryonic Antigen (CEA) Antibody

abx020545-1mg 1 mg
EUR 690
  • Shipped within 5-10 working days.

Carcinoembryonic Antigen (CEA) Antibody

abx020546-1mg 1 mg
EUR 690
  • Shipped within 5-10 working days.

Carcinoembryonic Antigen (CEA) Antibody

20-abx175703
  • EUR 342.00
  • EUR 133.00
  • EUR 954.00
  • EUR 481.00
  • EUR 286.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-12 working days.

Carcinoembryonic Antigen (CEA) Antibody

20-abx102321
  • EUR 300.00
  • EUR 133.00
  • EUR 787.00
  • EUR 411.00
  • EUR 258.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Carcinoembryonic Antigen (CEA) Antibody

20-abx102322
  • EUR 300.00
  • EUR 133.00
  • EUR 787.00
  • EUR 411.00
  • EUR 258.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Carcinoembryonic Antigen (CEA) Antibody

20-abx102323
  • EUR 328.00
  • EUR 133.00
  • EUR 913.00
  • EUR 467.00
  • EUR 286.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Carcinoembryonic Antigen (CEA) Antibody

20-abx102324
  • EUR 328.00
  • EUR 133.00
  • EUR 913.00
  • EUR 467.00
  • EUR 286.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Carcinoembryonic Antigen (CEA) Antibody

abx120020-1mg 1 mg
EUR 787
  • Shipped within 5-10 working days.

Carcinoembryonic Antigen (CEA) Antibody

20-abx128498
  • EUR 300.00
  • EUR 133.00
  • EUR 787.00
  • EUR 411.00
  • EUR 258.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Carcinoembryonic Antigen (CEA) Antibody

20-abx128499
  • EUR 300.00
  • EUR 133.00
  • EUR 787.00
  • EUR 411.00
  • EUR 258.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Carcinoembryonic Antigen (CEA) Antibody

20-abx171571
  • EUR 704.00
  • EUR 356.00
  • 1 mg
  • 200 ug
  • Please enquire.

Carcinoembryonic Antigen (CEA) Antibody

20-abx171572
  • EUR 843.00
  • EUR 439.00
  • 1 mg
  • 200 ug
  • Please enquire.

Carcinoembryonic Antigen (CEA) Antibody

20-abx270133
  • EUR 467.00
  • EUR 537.00
  • EUR 272.00
  • EUR 815.00
  • EUR 356.00
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests
  • Shipped within 5-15 working days.

Carcinoembryonic Antigen (CEA) Antibody

20-abx270165
  • EUR 467.00
  • EUR 537.00
  • EUR 272.00
  • EUR 815.00
  • EUR 356.00
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests
  • Shipped within 5-15 working days.

Carcinoembryonic Antigen (CEA) Antibody

20-abx270190
  • EUR 467.00
  • EUR 537.00
  • EUR 272.00
  • EUR 815.00
  • EUR 356.00
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests
  • Shipped within 5-15 working days.

Carcinoembryonic Antigen (CEA) Antibody

abx231576-100ug 100 ug
EUR 481
  • Shipped within 5-12 working days.

Human carcinoembryonic antigen (CEA) antigen

CEA15-N-100 100 ug
EUR 225

Active Carcinoembryonic Antigen (CEA)

4-APA150Hu04
  • EUR 648.35
  • EUR 276.00
  • EUR 2156.32
  • EUR 785.44
  • EUR 1470.88
  • EUR 497.00
  • EUR 5240.80
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: P06731
  • Buffer composition: 20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 15.0kDa
  • Isoelectric Point: 6.7
Description: Recombinant Human Carcinoembryonic Antigen expressed in: Available from E.coli, Yeast, Baculovirus and Mammalian cells

Eukaryotic Carcinoembryonic Antigen (CEA)

4-EPA150Hu61
  • EUR 512.16
  • EUR 240.00
  • EUR 1645.60
  • EUR 615.20
  • EUR 1130.40
  • EUR 406.00
  • EUR 3964.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: P06731
  • Buffer composition: 20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 73.0kDa
  • Isoelectric Point: 5.4
Description: Recombinant Human Carcinoembryonic Antigen expressed in: 293F cell

Recombinant Carcinoembryonic Antigen (CEA)

4-RPA150Hu01
  • EUR 404.64
  • EUR 211.00
  • EUR 1242.40
  • EUR 480.80
  • EUR 861.60
  • EUR 334.00
  • EUR 2956.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: P06731
  • Buffer composition: PBS, pH 7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 16.0kDa
  • Isoelectric Point: Inquire
Description: Recombinant Human Carcinoembryonic Antigen expressed in: E.coli

Recombinant Carcinoembryonic Antigen (CEA)

4-RPA150Hu02
  • EUR 404.64
  • EUR 211.00
  • EUR 1242.40
  • EUR 480.80
  • EUR 861.60
  • EUR 334.00
  • EUR 2956.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: P06731
  • Buffer composition: 20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 15.0kDa
  • Isoelectric Point: 5.9
Description: Recombinant Human Carcinoembryonic Antigen expressed in: E.coli

Recombinant Carcinoembryonic Antigen (CEA)

4-RPA150Hu03
  • EUR 404.64
  • EUR 211.00
  • EUR 1242.40
  • EUR 480.80
  • EUR 861.60
  • EUR 334.00
  • EUR 2956.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: P06731
  • Buffer composition: PBS, pH 7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 17.7kDa
  • Isoelectric Point: 5.9
Description: Recombinant Human Carcinoembryonic Antigen expressed in: E.coli

Recombinant Carcinoembryonic Antigen (CEA)

4-RPA150Hu04
  • EUR 404.64
  • EUR 211.00
  • EUR 1242.40
  • EUR 480.80
  • EUR 861.60
  • EUR 334.00
  • EUR 2956.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: P06731
  • Buffer composition: PBS, pH 7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 15.3kDa
  • Isoelectric Point: Inquire
Description: Recombinant Human Carcinoembryonic Antigen expressed in: E.coli

Recombinant Carcinoembryonic Antigen (CEA)

4-RPA150Mu01
  • EUR 490.66
  • EUR 234.00
  • EUR 1564.96
  • EUR 588.32
  • EUR 1076.64
  • EUR 391.00
  • EUR 3762.40
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: Q3UKK2
  • Buffer composition: 20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 16.4kDa
  • Isoelectric Point: 8.7
Description: Recombinant Mouse Carcinoembryonic Antigen expressed in: E.coli

Recombinant Carcinoembryonic Antigen (CEA)

4-RPA150Mu02
  • EUR 485.28
  • EUR 233.00
  • EUR 1544.80
  • EUR 581.60
  • EUR 1063.20
  • EUR 388.00
  • EUR 3712.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: Q3UKK2
  • Buffer composition: 100mMNaHCO3, 500mMNaCl, pH8.3, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 26.3kDa
  • Isoelectric Point: 6
Description: Recombinant Mouse Carcinoembryonic Antigen expressed in: E.coli

Recombinant Carcinoembryonic Antigen (CEA)

4-RPA150Ra01
  • EUR 499.62
  • EUR 236.00
  • EUR 1598.56
  • EUR 599.52
  • EUR 1099.04
  • EUR 397.00
  • EUR 3846.40
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: Q63111
  • Buffer composition: 20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 26.1kDa
  • Isoelectric Point: 5.1
Description: Recombinant Rat Carcinoembryonic Antigen expressed in: E.coli

Carcinoembryonic Antigen (CEA) Antibody (FITC)

20-abx270431
  • EUR 523.00
  • EUR 606.00
  • EUR 300.00
  • EUR 940.00
  • EUR 384.00
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests
  • Shipped within 5-15 working days.

Carcinoembryonic Antigen (CEA) Antibody (FITC)

20-abx270463
  • EUR 523.00
  • EUR 606.00
  • EUR 300.00
  • EUR 940.00
  • EUR 384.00
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests
  • Shipped within 5-15 working days.

Carcinoembryonic Antigen (CEA) Antibody (FITC)

20-abx270488
  • EUR 523.00
  • EUR 606.00
  • EUR 300.00
  • EUR 940.00
  • EUR 384.00
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests
  • Shipped within 5-15 working days.

Carcinoembryonic Antigen (CEA) Antibody (APC)

20-abx270663
  • EUR 704.00
  • EUR 829.00
  • EUR 370.00
  • EUR 1330.00
  • EUR 495.00
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests
  • Shipped within 5-15 working days.

Carcinoembryonic Antigen (CEA) Antibody (APC)

20-abx270695
  • EUR 704.00
  • EUR 829.00
  • EUR 370.00
  • EUR 1330.00
  • EUR 495.00
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests
  • Shipped within 5-15 working days.

Carcinoembryonic Antigen (CEA) Antibody (APC)

20-abx270720
  • EUR 704.00
  • EUR 829.00
  • EUR 370.00
  • EUR 1330.00
  • EUR 495.00
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests
  • Shipped within 5-15 working days.

Carcinoembryonic Antigen (CEA) Antibody (PE)

20-abx270895
  • EUR 606.00
  • EUR 718.00
  • EUR 328.00
  • EUR 1135.00
  • EUR 439.00
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests
  • Shipped within 5-15 working days.

Carcinoembryonic Antigen (CEA) Antibody (PE)

20-abx270927
  • EUR 606.00
  • EUR 718.00
  • EUR 328.00
  • EUR 1135.00
  • EUR 439.00
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests
  • Shipped within 5-15 working days.

Carcinoembryonic Antigen (CEA) Antibody (PE)

20-abx270952
  • EUR 606.00
  • EUR 718.00
  • EUR 328.00
  • EUR 1135.00
  • EUR 439.00
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests
  • Shipped within 5-15 working days.

Carcinoembryonic Antigen (CEA) Antibody (Biotin)

20-abx271833
  • EUR 314.00
  • EUR 217.00
  • EUR 857.00
  • EUR 439.00
  • EUR 272.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-12 working days.

Carcinoembryonic Antigen (CEA) Antibody (Biotin)

20-abx272619
  • EUR 342.00
  • EUR 217.00
  • EUR 996.00
  • EUR 495.00
  • EUR 300.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-15 working days.

Carcinoembryonic Antigen (CEA) Antibody Pair

20-abx370130
  • EUR 1107.00
  • EUR 732.00
  • 10 × 96 tests
  • 5 × 96 tests
  • Shipped within 5-15 working days.

Carcinoembryonic Antigen/CEA Monoclonal Antibody

EM1061-100ul 100ul
EUR 279
Description: A Mouse Monoclonal antibody against Carcinoembryonic Antigen/CEA from Human/ Rat/ Mouse. This antibody is tested and validated for IHC

Carcinoembryonic Antigen/CEA Monoclonal Antibody

EM1061-50ul 50ul
EUR 207
Description: A Mouse Monoclonal antibody against Carcinoembryonic Antigen/CEA from Human/ Rat/ Mouse. This antibody is tested and validated for IHC

Carcinoembryonic Antigen(CEA) Mouse Monoclonal Antibody

38016-100ul 100ul
EUR 252

Carcinoembryonic Antigen(CEA) Mouse Monoclonal Antibody

38016-50ul 50ul
EUR 187

Carcinoembryonic Antigen (CEA) Polyclonal Antibody (Rat)

4-PAA150Hu01
  • EUR 188.00
  • EUR 1586.00
  • EUR 415.00
  • EUR 226.00
  • EUR 188.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
  • Sequence of the immunogen: CEA (Pro93~Val221)
  • Buffer composition: PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Description: A Rabbit polyclonal antibody against Rat Carcinoembryonic Antigen (CEA)

Carcinoembryonic Antigen (CEA) Polyclonal Antibody (Human)

4-PAA150Hu02
  • EUR 188.00
  • EUR 1586.00
  • EUR 415.00
  • EUR 226.00
  • EUR 188.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
  • Sequence of the immunogen: CEA (Ala566~Gly698)
  • Buffer composition: PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Description: A Rabbit polyclonal antibody against Human Carcinoembryonic Antigen (CEA)

Carcinoembryonic Antigen (CEA) Polyclonal Antibody (Human)

4-PAA150Hu03
  • EUR 188.00
  • EUR 1586.00
  • EUR 415.00
  • EUR 226.00
  • EUR 188.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
  • Sequence of the immunogen: CEA (Gly75~Asn219)
  • Buffer composition: PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Description: A Rabbit polyclonal antibody against Human Carcinoembryonic Antigen (CEA)

Carcinoembryonic Antigen (CEA) Polyclonal Antibody (Mouse)

4-PAA150Mu01
  • EUR 205.00
  • EUR 1863.00
  • EUR 478.00
  • EUR 251.00
  • EUR 196.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
  • Sequence of the immunogen: CEA (Thr85~Phe222)
  • Buffer composition: 0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Description: A Rabbit polyclonal antibody against Mouse Carcinoembryonic Antigen (CEA)

Human Carcinoembryonic Antigen (CEA) Protein

20-abx166414
  • EUR 578.00
  • EUR 258.00
  • EUR 1678.00
  • EUR 676.00
  • EUR 425.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Human Carcinoembryonic Antigen (CEA) Protein

20-abx065719
  • EUR 578.00
  • EUR 258.00
  • EUR 1678.00
  • EUR 676.00
  • EUR 425.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Mouse Carcinoembryonic Antigen (CEA) Protein

20-abx065720
  • EUR 690.00
  • EUR 286.00
  • EUR 2110.00
  • EUR 815.00
  • EUR 495.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Human Carcinoembryonic Antigen (CEA) Protein

20-abx065721
  • EUR 578.00
  • EUR 258.00
  • EUR 1678.00
  • EUR 676.00
  • EUR 425.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Mouse Carcinoembryonic Antigen (CEA) Protein

20-abx065722
  • EUR 676.00
  • EUR 286.00
  • EUR 2082.00
  • EUR 801.00
  • EUR 481.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Human Carcinoembryonic Antigen (CEA) Protein

20-abx065723
  • EUR 578.00
  • EUR 258.00
  • EUR 1678.00
  • EUR 676.00
  • EUR 425.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-12 working days.

Human Carcinoembryonic Antigen (CEA) Protein

20-abx651474
  • EUR 718.00
  • EUR 286.00
  • EUR 2221.00
  • EUR 857.00
  • EUR 509.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Rat Carcinoembryonic Antigen (CEA) Protein

20-abx652080
  • EUR 704.00
  • EUR 286.00
  • EUR 2151.00
  • EUR 829.00
  • EUR 495.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Human Carcinoembryonic Antigen (CEA) ELISA

LF-EK0161 1×96T
EUR 603

anti-Carcinoembryonic Antigen/CEA (10E1)

LF-MA20354 100 ug
EUR 354
Description: Mouse monoclonal to Carcinoembryonic Antigen (CEA)

Carcinoembryonic Antigen (CEA) / CD66 (C66/1260) Antibody

BNUM1260-50 50uL
EUR 395
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 ( C66/1260), 1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1291) Antibody

BNUM1291-50 50uL
EUR 395
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/1291), 1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1292) Antibody

BNUM1292-50 50uL
EUR 395
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/1292), 1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1260) Antibody

BNUB1260-100 100uL
EUR 209
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 ( C66/1260), Concentration: 0.2mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1260) Antibody

BNUB1260-500 500uL
EUR 458
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 ( C66/1260), Concentration: 0.2mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1291) Antibody

BNUB1291-100 100uL
EUR 209
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/1291), Concentration: 0.2mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1291) Antibody

BNUB1291-500 500uL
EUR 458
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/1291), Concentration: 0.2mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1292) Antibody

BNUB1292-100 100uL
EUR 209
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/1292), Concentration: 0.2mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1292) Antibody

BNUB1292-500 500uL
EUR 458
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/1292), Concentration: 0.2mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1983R) Antibody

BNUB1983-100 100uL
EUR 264
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/1983R), Concentration: 0.2mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1983R) Antibody

BNUB1983-50 50uL
EUR 405
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/1983R), 1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1983R) Antibody

BNUB1983-500 500uL
EUR 513
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/1983R), Concentration: 0.2mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (rC66/1009) Antibody

BNUB2054-100 100uL
EUR 264
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (rC66/1009), Concentration: 0.2mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (rC66/1009) Antibody

BNUB2054-50 50uL
EUR 405
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (rC66/1009), 1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (rC66/1009) Antibody

BNUB2054-500 500uL
EUR 513
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (rC66/1009), Concentration: 0.2mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/2055R) Antibody

BNUB2055-100 100uL
EUR 264
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/2055R), Concentration: 0.2mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/2055R) Antibody

BNUB2055-50 50uL
EUR 405
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/2055R), 1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/2055R) Antibody

BNUB2055-500 500uL
EUR 513
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/2055R), Concentration: 0.2mg/mL

Efficiency of Repeat BinaxNOW SARS-CoV-2 Antigen Testing in a Neighborhood Setting, Wisconsin, November-December 2020 

Repeating the BinaxNOW antigen take a look at for SARS-CoV-2 by two teams of readers inside 30 minutes resulted in excessive concordance (98.9%) in 2,110 encounters. BinaxNOW take a look at sensitivity was 77.2% (258/334) in comparison with real-time reverse transcription-polymerase chain response. Similar day antigen testing didn’t considerably enhance take a look at sensitivity whereas specificity remained excessive.

Rs2686344 and serum squamous cell carcinoma antigen may predict medical efficacy of neoadjuvant chemotherapy for cervical most cancers 

Goal: To guage the predictive worth of a single nucleotide polymorphism (SNP) rs2686344 and squamous cell carcinoma antigen (SCCAg) ranges within the medical efficacy of neoadjuvant chemotherapy (NACT) for cervical most cancers.

Strategies: A complete of 92 sufferers with stage IB2-IIIB carcinoma of the uterine cervix who acquired NACT remedy had been enrolled. The connection between the genotypes of SNP rs2686344 which is positioned on CAMKK2 on chromosome 12, SCCAg ranges and the response to NACT was analyzed. The connection between the SNP rs2686344 genotypes, SCCAg ranges, the response to NACT and the five-year survival price was evaluated.

Outcomes: The efficient group accounted for 84.85% in sufferers with low stage (≤3.5 ng/mL) of post-treatment SCCAg (post-SCCAg), whereas the ineffective group accounted for 15.15%. The post-SCCAg ranges and the genotypes of rs2686344 had been considerably correlated with NACT response (P = 0.003, and P = 0.006). In sufferers with CC or CT genotype of SNP rs2686344, efficient group accounted for 81.18%, whereas ineffective group accounted for 18.82%; For sufferers with TT genotype, efficient response group accounted for 28.57%, ineffective group accounted for 71.43%. Submit-SCCAg stage >3.5 ng/mL and TT genotype of SNP rs2686344 confirmed as unbiased threat elements for NACT response within the multivariate evaluation (P = 0.002, and P = 0.048). There was no vital distinction in 5-year general survival and 5-year disease-free survival between sufferers with completely different ranges of post-SCCAg, or amongst completely different rs2686344 genotypes.

Conclusion: The excessive stage of post-SCCAg (>3.5 ng/mL) and TT genotype of rs2686344 might counsel a better threat of poor response to NACT.

Antibody and antigen prevalence as indicators of ongoing transmission or elimination of visceral leishmaniasis: a modelling examine 

Background: Management of visceral leishmaniasis (VL) on the Indian subcontinent has been extremely profitable. Management efforts equivalent to indoor residual spraying and lively case detection will likely be scaled down and even halted over the approaching years. We explored how after scale-down, potential recurrence of VL instances could also be predicted based mostly on population-based surveys of antibody or antigenaemia prevalence.

Strategies: Utilizing a stochastic age-structured transmission mannequin of VL, we predicted tendencies in case incidence and biomarker prevalence over time after cutting down management efforts when the goal of three successive years with out VL instances has been achieved. Subsequent, we correlated biomarker prevalence with the prevalence of latest VL instances inside 10 years of scale-down.

Outcomes: Incidence of at least one new VL case in a inhabitants of 10,000 was extremely correlated with the seroprevalence and antigenaemia prevalence for the time being of scale-down, or one or two years afterwards. Receiver working attribute curves indicated that biomarker prevalence in adults offered essentially the most predictive data, and seroprevalence was a extra informative predictor of latest VL instances than antigenaemia prevalence. Thresholds for biomarker prevalence to foretell prevalence of latest VL instances with excessive certainty had been strong to variation in pre-control endemicity.

Dialogue: The chance of recrudescence of VL after cutting down management efforts will be monitored and mitigated by the use of population-based surveys. Our findings spotlight that speedy point-of-care diagnostic instruments to evaluate (ideally) seroprevalence or (in any other case) antigenaemia within the normal inhabitants may very well be a key ingredient of sustainable VL management.

Human colorectal cancer-associated carbohydrate antigen on annexin A2 protein 

Most cancers-associated antigens will not be solely a very good marker for monitoring most cancers development however are additionally helpful for molecular goal remedy. In this examine, we aimed to generate a monoclonal antibody that preferentially reacts with colorectal most cancers cells relative to noncancerous gland cells. We ready antigens composed of HT-29 colorectal most cancers cell lysates that had been adsorbed by antibodies to sodium butyrate-induced enterocytically differentiated HT-29 cells. Subsequently, we generated a monoclonal antibody, designated 12G5A, which reacted with HT-29 colon most cancers cells, however not with sodium butyrate-induced differentiated HT-29 cells.

Immunohistochemical staining revealed 12G5A immunoreactivity in all 73 colon most cancers tissue specimens examined at numerous levels, however little or no immunoreactivity in noncancerous gland cells. Notably, excessive 12G5A immunoreactivity, which was decided as greater than 50% of colon most cancers cells intensively stained with 12G5A antibody, exhibited considerably increased affiliation with a poor general survival price of sufferers with colorectal most cancers (P = 0.0196) and unfavorable progression-free survival price of sufferers with colorectal most cancers (P = 0.0418). Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, si-RNA silencing evaluation, enzymatic deglycosylation, and tunicamycin remedy revealed that 12G5A acknowledged the glycosylated epitope on annexin A2 protein.

Our findings point out that 12G5A recognized a cancer-associated glycosylation epitope on annexin A2, whose expression was associated to unfavorable colorectal most cancers habits. KEY MESSAGE: • 12G5A monoclonal antibody acknowledged a colorectal cancer-associated epitope. • 12G5A antibody acknowledged the N-linked glycosylation epitope on annexin A2. • 12G5A immunoreactivity was associated to unfavorable colorectal most cancers habits.

, , , , , , , , , , , ,

Post navigation

Leave a Reply

Your email address will not be published. Required fields are marked *